|Home | About | Journals | Submit | Contact Us | Français|
Mitotic homologous recombination (HR) is a critical pathway for the accurate repair of DNA double strand breaks (DSBs) and broken replication forks. While generally error-free, HR can occur between misaligned sequences, resulting in deleterious sequence rearrangements that can contribute to cancer and aging. To learn more about the extent to which HR occurs in different tissues during the aging process, we used Fluorescent Yellow Direct Repeat (FYDR) mice in which an HR event in a transgene yields a fluorescent phenotype. Here, we show tissue-specific differences in the accumulation of recombinant cells with age. Unlike pancreas, which shows a dramatic 23-fold increase in recombinant cell frequency with age, skin shows no increase in vivo. In vitro studies indicate that juvenile and aged primary fibroblasts are similarly able to undergo HR in response to endogenous and exogenous DNA damage. Therefore, the lack of recombinant cell accumulation in the skin is most likely not due to an inability to undergo de novo HR events. We propose that tissue-specific differences in the accumulation of recombinant cells with age result from differences in the ability of recombinant cells to persist and clonally expand within tissues.
The accumulation of somatic mutations is considered to be a major cause of cancer and aging [1,2]. Mutations are believed to accumulate with age due to a combination of increased levels of endogenous DNA damaging agents, such as reactive oxygen species , and decreased efficiency and fidelity of DNA repair [4–8]. Double strand breaks (DSBs) are considered to be among the most toxic and mutagenic lesions that mammalian cells experience. In the context of aging, the steady-state levels of DNA DSBs have been shown to increase with age [9,10]. Furthermore, the improper repair of DSBs can lead to large scale genomic sequence rearrangements, such as translocations, insertions, and deletions , and an increased frequency of such rearrangements is often observed in aged cells [12–16]. Consistent with these findings, it has also been shown that deficiencies in the ability to repair DSBs cause accelerated aging . Together, these data suggest that DSBs and their repair are critical factors in the aging process.
Mammalian cells use two main pathways for the repair of DSBs: non-homologous end joining (NHEJ) and homologous recombination (HR). NHEJ directly rejoins DSBs in a sequence independent manner, often resulting in small sequence alterations [18,19]. In contrast, HR uses homologous sequences present on the sister chromatid or homologous chromosome as templates for repair, enabling the repair of DSBs with high fidelity . NHEJ is the preferred pathway for the repair of DSBs during G0/G1 phases of the cell cycle, whereas HR is important during late S/G2 . Although HR is generally error-free, exchanges between misaligned sequences that lead to insertions, deletions, translocations, and loss of heterozygosity (LOH) can occur. Since over 40% of the genome is comprised of repeated elements , during G0/G1, NHEJ is preferred to minimize deleterious rearrangements . In contrast, when a sister chromatid is present during S phase, HR is preferred since it plays an essential role in the repair of DSBs that arise as a result of replication fork breakdown (i.e., replication fork encounter with a blocking DNA lesion or a single strand gap [23–27]). Indeed, HR is the only DNA repair pathway that can accurately reinsert the broken DNA end to restart the replication fork . If DSBs at broken forks are instead acted upon by NHEJ, ends from independent loci may be joined, which will inevitably lead to large scale sequence rearrangements. Thus, in order to prevent mutation formation, it is critical that cells initiate the appropriate DSB repair pathway.
Germline mutations in genes that modulate DSB repair cause premature aging syndromes. For example, Werner syndrome is caused by a mutation in the RecQ-like DNA helicase WRN [28,29]. WRN is believed to play an important role in the resolution of HR intermediates [30,31], and loss of function of WRN is associated with an increased frequency of deleterious recombination events [32–34]. In addition, heritable mutations in ATM, a protein that plays a critical role in initiating DSB repair , result in ataxia telangiectasia, a disease that is associated with symptoms of premature aging . Interestingly, ATM−/− cells show an increased frequency of HR and are particularly susceptible to error-prone HR [36–39]. Finally, mice with germline mutations in Ku80 (Ku86), an integral protein in NHEJ, exhibit an accelerated aging phenotype . Together, these results show that defects in DSB repair can promote aging.
Given its potentially pivotal role in suppressing aging and age-related diseases, there is great interest in understanding how DSB repair by HR changes in somatic cells with age. In previous studies, LOH events were analyzed to measure the accumulation of cells harboring recombined DNA during aging [41,42]. Since LOH can be caused by multiple mechanisms, careful analysis of DNA must be done in order to reveal the fraction of events resulting from HR. Using such analyses, it has been shown that HR is responsible for a large fraction of LOH events that accumulate with increasing age in both lymphocytes and kidney cells [41,42], suggesting that HR contributes significantly to DNA rearrangements that occur during aging. Due to technical limitations, little is known about the importance of HR in other cells types. In particular, unless a cell can be cultured ex vivo, the accumulation of recombinant cells cannot be studied using these approaches.
In addition to these studies of HR and LOH, the accumulation of point mutations in various tissues has also been measured by using mouse models for mutation detection [43–46]. Intriguingly, the effect of age on mutation frequency appears to be strongly tissue-dependent, and differences in mutation accumulation do not correlate with cell proliferation within the tissue. For example, in tissues with low proliferation rates, an increase in mutant cell frequency with age is seen in the heart [45,46] but not in the brain [43–45,47]. In addition, tissues that exhibit high proliferation rates, mutant cell frequency increases in the small intestine [46,48] but not in the testis [43,45,49]. Thus, although the accumulation of mutations differs among tissues, the reasons for these differences are not yet understood.
Here, we set out to investigate the effects of aging on the frequency of HR events in two different tissue types in vivo. To study recombination in vivo, we developed the Fluorescent Yellow Direct Repeat (FYDR) mice, in which a HR event at an integrated transgene yields a fluorescent cell . A comparison of pancreatic and skin tissues shows that while recombinant cells accumulate in the pancreas with age, the frequency of recombinant cells in skin does not change. Previously, by using in situ imaging analysis, we had shown that the accumulation of recombinant cells in aged pancreata results not only from de novo recombination events but also from clonal expansion of existing recombinant cells . To determine if the lack of accumulation in skin results from a decrease in the demand for HR with age, we analyzed primary fibroblasts from FYDR mice in vitro. Neither the spontaneous rate of HR nor the ability of cells to use HR in response to an exogenous recombinogen changes with age, suggesting that fibroblasts within aged skin are able to undergo de novo recombination events in vivo. Thus, the lack of accumulation of recombinant cells in aged skin may be due to the absence of extensive clonal expansion in skin with age.
C57BL/6 FYDR mice were described previously . Positive control FYDR-Recombined (FYDR-Rec) mice arose spontaneously from an HR event in a FYDR parental gamete, and all cells carry the full-length EYFP coding sequence . FYDR cohorts had equal ratios of males to females. Controls were sex and age matched, except aged negative control C57BL/6 were 47–85 weeks old and the aged positive control FYDR-Rec mice were 52–68 weeks old.
Ventral skin or ears were isolated, minced, and incubated at 37°C in 4 mg/ml collagenase/dispase (Roche Applied Sciences). After 1 hour, two volumes of fibroblast medium was added [DMEM, 15% FBS, 100 units/ml penicillin, 100 μg/ml streptomycin, 5 μg/ml amphotericin B (Sigma)]. After 24 hours at 37°C and 5% CO2, cells were triturated, filtered (70-μm mesh; Falcon), and analyzed by flow cytometry (ventral skin cells) or seeded into dishes (ear fibroblasts). For all in vitro studies, primary ear fibroblasts were isolated from 5 juvenile (4 weeks old) and 5 aged (62–89 weeks old) female FYDR mice in parallel. After pooling cells from mice within each cohort, ~1 million cells were analyzed by flow cytometry to determine the initial frequency of recombinant cells within each age group. The remaining cells were plated for in vitro studies.
Pancreatic cells were disaggregated as described previously . Disaggregated pancreatic or skin cells were pelleted and resuspended in 350 μl OptiMEM (Invitrogen), filtered (35 μm), and analyzed with a Becton Dickinson FACScan flow cytometer (excitation 488 nm, argon laser). Live cells were gated by using forward and side scatter. On average, ~1 million cells were analyzed per sample for flow cytometry.
Using pooled primary ear fibroblasts isolated from 5 juvenile and 5 aged FYDR mice, 3 rate experiments were plated in parallel for each age cohort. For each rate experiment, ~104 cells were seeded into 24 independent cultures. Cultures were expanded and analyzed by flow cytometry once the density reached ~106 cells per well. The method of p0 was used to determine the rate of recombination per cell division as described [53,54]. Rate experiments were repeated with fibroblasts from different cohorts of mice 3 times. For frequency analysis, the final frequencies for each culture of the rate experiment were averaged.
Alkaline comet assay experiments were performed using pooled primary ear fibroblasts isolated from 5 juvenile and 5 aged FYDR mice. Two independent experiments with 3 replicate slides per sample were carried out at dim light using a commercially available comet assay kit according to the manufacturer’s protocol (Trevigen, Gaithersburg, MD). Briefly, cells were trypsinized, rinsed with ice cold Ca2+ and Mg2+ free PBS and counted. 2×104 cells were then suspended in 80 μl of 1% molten low melting point agarose and placed onto comet assay slides (Trevigen). After incubation at 4°C for 30 min slides were immersed in pre-chilled lysis solution (Trevigen) for 60 min at 4°C, rinsed with ice cold PBS and incubated in an alkaline solution (pH>13) at room temperature for 40 min, allowing DNA unwinding. Next, slides were subjected to electrophoresis at 30V for 30 min followed by rinsing 5 min with 70% ethanol. Slides were kept in a moist chamber overnight at 4°C, stained with ethidium bromide and analyzed on a Nikon Fluorescence microscope using Komet 5.5 Software (Andor Technologies, South Windsor, CT). 99 cells per slide were quantified for percent comet tail DNA and Olive tail moment.
Primary ear fibroblasts from 5 juvenile and 5 aged FYDR mice were pooled and seeded at 2 × 105 cells per well. After 24 hours, 10 μM BrdU was added to the culture media. Cells were harvested after undergoing two population doublings and analyzed for SCE frequency as previously described . SCEs were counted in a blinded fashion from 2 independent experiments with each experiment containing cells combined from 5 mice per cohort.
Primary ear fibroblasts from 5 juvenile and 5 aged FYDR mice were pooled and seeded at 5 × 105 cells per 100 mm dish. After 24 hours, triplicate or quadruplicate samples were exposed to 0.5 μg/ml mitomycin-C (CAS No 50-07-7) in Dulbecco’s Modified Eagle’s Medium (Sigma) for 1 hour. After 72 hours, samples were analyzed by flow cytometry. Population growth was determined from the number of viable cells per dish. Experiments were repeated with fibroblasts from different cohorts of mice 3 times.
To study HR in vivo, we previously developed FYDR mice that carry a direct repeat recombination substrate containing two differently mutated copies of the coding sequence for enhanced yellow fluorescent protein (EYFP). An HR event can restore full length EYFP coding sequence, thus yielding a fluorescent cell (Fig. 1A). One method for determining the in vivo frequency of recombinant cells is to analyze disaggregated tissue by flow cytometry [51,56]. Briefly, for both pancreas and skin we compared fluorescence intensities in disaggregated tissue from negative control and positive control (FYDR-Recombined ) mice and established a region (R2) that excludes negative control cells (Fig. 1B, note: identical criteria were used to establish an R2 region for pancreas ). Over 21 million skin cells and over 34 million pancreatic were analyzed by flow cytometry and 0 and 1 cell appeared in the R2 region established for skin and pancreas, respectively, indicating an extremely low frequency of false positives. Thus, while the actual number of fluorescent recombinant cells may be underestimated for both skin and pancreas, virtually all false positive cells are eliminated.
The distribution of spontaneous recombinant cell frequencies in pancreatic tissue from 100 mice aged 4–10 weeks was previously established and published elsewhere  (Fig. 1C, black bars). To compare homologous recombination between pancreas and skin, skin from 100 mice aged 4–10 weeks was similarly analyzed (Fig. 1C, gray bars). Although recombinant cell frequency is variable among mice for both tissues, the median recombinant cell frequency is statistically significantly higher for pancreas than for skin (Fig. 1D). Additionally, analysis of independent mice shows that ~20% of mice contained more than 20 recombinant cells per million in the pancreas, as compared to 4% for skin, suggesting that the distribution of recombinant cell frequencies among mice differs between tissues. High spontaneous frequencies of recombinant cells observed in some samples may result from an early HR event followed by clonal expansion of the resulting fluorescent cell. These data, therefore, raise the possibility that fluorescent recombinant cells within the pancreas may be more likely to clonally expand than those contained within the skin.
It is formally possible that differences in recombinant cell frequencies for pancreatic versus skin tissues may be due to differences in the expression levels of the FYDR transgene. Clearly, if EYFP is expressed at lower levels, it will be more difficult to detect recombinant cells. To determine if the increased frequency of recombinant cells in pancreatic tissue is due to increased EYFP expression, we analyzed pancreatic and skin tissues from positive control FYDR-Rec mice that carry the full-length EYFP coding sequence in every cell . EYFP expression was, in fact, statistically significantly higher in pancreatic (~52%) versus skin (~30%) tissues (Fig. 1E). Given that the positive control FYDR-Rec mice express EYFP under an identical promoter and at the same locus as the FYDR recombination substrate, it is likely that there is higher expression in pancreatic tissue of the FYDR mice as well. This higher level of expression in the pancreas compared to skin may partially account for the higher median recombinant cell frequency in pancreatic compared to skin tissues and for the apparent differences in the distribution of recombinant cell frequencies between the tissue types. The observation that a larger proportion of the mice show very high frequencies of recombinant cells in the pancreas compared to skin raises the possibility that recombinant cells in the pancreas have the ability to persist and clonally expand, while those in the skin do not. We had previously established that recombinant cells accumulate in the pancreas with age . We, therefore, extended these studies to explore the effects of aging on the accumulation of recombinant cells in the skin.
To explore the effects of aging, recombinant cells were quantified in two different age groups: ‘juvenile’ (4 weeks old) and ‘aged’ (62–89 weeks old). For pancreatic tissue, the median frequency of recombinant pancreatic cells dramatically increased ~23 fold from juvenile to aged mice (Fig. 2A; shows previously published data  combined with new results). Given that we observed no statistically significant difference in EYFP expression with age in pancreatic cells (Fig. 2B), these data indicate that recombinant cells accumulate in the pancreas with age. For skin tissue, analysis of the recombinant cell frequency shows that the median is virtually identical between the juvenile and aged cohorts (Fig. 2C). Comparison of EYFP expression in skin with age shows no statistically significant difference between juvenile and aged mice (Fig. 2D). Thus, unlike in pancreatic tissue, recombinant fluorescent cells do not accumulate in cutaneous tissue with age.
Previous studies  show that accumulation of recombinant cells in the pancreas is caused by both de novo recombination events and clonal expansion. Therefore, the fact that recombinant cells do not accumulate in skin can be explained by either a lack of de novo recombination events, a lack of persistence of cells that harbor recombined DNA, or a lack of clonal expansion with age (or some combination of these factors).
A lack of de novo recombination events may result from a reduced ability of aged cells to under HR at the FYDR substrate. To test this hypothesis, primary ear fibroblasts from juvenile and aged mice were cultured in vitro. When cells from juvenile and aged mice were allowed to expand in vitro, we observed that aged cells had a statistically significantly longer doubling time (Fig. 3A). While aged cells grew more slowly, cultures for both cohorts showed a similar increase in the frequency of recombinant cells as a consequence of de novo recombination events that occurred as the cells divided (Fig. 3B). Therefore, we conclude that HR is an active repair process in dividing cells in vitro for both age groups and that cells from both age cohorts are similarly susceptible to de novo recombination events. Furthermore, we estimated the rate of recombination in juvenile versus aged primary fibroblasts using the p0 method [53,54]. We found that there is no statistically significant difference in the rate of recombination between juvenile and aged cells (Fig. 3B). To determine if differences in the EYFP expression levels exist, fibroblasts from juvenile and aged positive control mice were cultured in parallel with rate experiments. Results show that there is no significant difference in EYFP expression with age in vitro (data not shown), indicating that differences in EYFP expression do not affect the apparent rates of HR. Thus, these data suggest that juvenile and aged cells are comparable in their HR capacity.
The rate of HR is partially dependent on the site of integration of the recombination substrate . To determine if the relationship between juvenile and aged cells is genome-wide, the frequency of another type of HR event, namely, sister chromatid exchanges (SCEs), was measured using an independent method. For SCE analysis, sister chromatids are differentially stained by culturing cells in the presence of the base analog 5-bromo-2′-deoxyuridine (BrdU) for two cell divisions. Recombination events that occur during these two replication cycles can be visualized in metaphase spreads (Fig. 3C). Blinded analysis of SCEs from juvenile and aged cells shows no statistical difference in the frequency of SCEs (Fig. 3D). Thus, since the rate of HR, as measured at the FYDR locus and by SCE analysis, is not statistically different between juvenile and aged fibroblasts, the lack of accumulation of recombinant cells in skin with age does not result from a suppression of HR.
DNA damage is known to induce HR, and therefore the rate of HR depends upon the amount of damage present within cells. To determine if the lack of recombinant cell accumulation in the skin might be due to diminished need to use HR, we assessed the amount of DNA damage within primary fibroblasts. For these studies, we evaluated the levels of single-strand breaks and alkali sensitive sites in juvenile and aged cells using the Comet assay. The average olive tail moment and percent tail DNA are two different ways to analyze the amount of DNA damage from Comet data . The averages for both olive tail moment (Fig. 3E) and percent tail DNA (Fig. 3F) are not statistically different between juvenile and aged fibroblasts, suggesting that the number of spontaneous single-strand breaks and alkali sensitive sites does not differ between these age cohorts. Therefore, we conclude that it is unlikely that differences in spontaneous levels of DNA damage explain the lack of accumulation of recombinant cells in skin.
Although fibroblasts cultured from juvenile and aged mice are similarly able to recombine in the presence of spontaneous damage, the ability to respond to exogenous DNA damage may change with age. To determine if aged cells are differentially sensitive to exogenous DNA damage, juvenile and aged fibroblasts were treated in vitro with the cross-linking agent and potent recombinogen mitomycin-C (MMC). Cell proliferation and recombinant cell frequency were analyzed 72 hours post mock- or MMC-treatment. Compared to mock-treated cells, juvenile and aged cells treated with MMC exhibit similar decreases in cell densities (Fig. 4A), indicating that growth inhibition following MMC treatment is similar in both age cohorts. For both juvenile and aged fibroblasts, analysis of recombinant cell frequency by flow cytometry shows a statistically significant increase in the frequency of recombinant cells for MMC-treated as compared to mock-treated cells (Fig. 4B). However, there is no statistically significant difference in the magnitude of induction between juvenile and aged cells, suggesting that juvenile and aged fibroblasts are similarly able to respond to exogenous DNA damage.
Many human progeroid syndromes, such as Werner Syndrome, Ataxia Telangiectasia, Cockayne Syndrome, and Trichothiodystrophy, are caused by defects in proteins that sense or repair DNA damage , indicating that the inability to accurately repair DNA damage contributes to aging. It is hypothesized that during the aging process, mutations accumulate within cells, causing diminished cell viability or capacity to carry out normal functions . Over time, the number of mutant cells within a tissue can increase, resulting in an overall reduction of tissue function. An increase in mutant cell frequency with age can result from a combination of factors, including an increase in DNA damage levels, a decrease in DNA repair capacity and/or an increase in the persistence or clonal expansion of mutant cells within a tissue. In these studies, we analyzed the relative contribution of these factors in the context of mutant cell accumulation with age in pancreas and skin.
HR events are an important class of mutations that are believed to contribute to the aging process [41,42]. Using the FYDR mice, data presented here combined with previous studies  shows that the frequency of recombinant cells within pancreatic tissue increases ~23-fold with age, while in skin tissue there is no accumulation. Other mouse models, including Big Blue [43,44], Muta Mouse , and LacZ , have been used to examine changes in mutation frequency with age in various tissues. Consistent with the data presented here, the effect of age on mutation frequency appears to be strongly tissue-dependent. Although none of these studies have reported mutation frequency in the pancreas, increases in mutant cell frequency with age have been shown in a number of other gastrointestinal tissues including the liver and small intestine [43–48]. Interestingly, no tissues have shown such a dramatic increase in mutant cell frequency with age as observed in the pancreas. In terms of the skin, one study showed a slight increase (~1.5-fold) in mutant cell frequency with age . While we cannot rule out that an increase in the frequency of recombinant cells in the skin may be seen in even older mice (the maximal lifespan of C57BL/6J mice is 110 ± 21 weeks ), this and other analogous studies [43–48] have shown little or no increase in mutant cell frequency is observed in skin with age, which is in sharp contrast to the large increase observed in pancreas and other gastrointestinal tissues.
We and others have found that the magnitude of the increase in mutant frequency with age did not correlate with cellular proliferation within the tissue. For example, very little accumulation of mutations was seen in testes [45,49], which contain highly proliferating cells . In contrast, in liver and heart, which are slow or non-proliferating tissues , there was a significant accumulation of mutations with age [44–47]. These data suggest that in addition to cell proliferation, other factors may also have a large impact on the accumulation of mutant cells with age. We hypothesize that the ability of mutant cells to persist and clonally expand within a tissue, rather than the rate of cell turnover, may have the greatest impact on the burden of mutant cell frequency with age.
For these studies, a comparison of pancreas and skin shows that while cells within the adult pancreas exhibit extremely low levels of proliferation (~1% of cells are in S phase ) and persist for long periods of time (turnover time of ~250–500 days ), cells within the skin have higher proliferation rates and relatively short persistence times (turnover time of ~7–60 days ). Despite the seemingly low level of proliferation in the pancreas, a dramatic increase in recombinant cell frequency is observed with age. In contrast to pancreas, skin does not appear to accumulate recombinant cells with age. Previously, we have analyzed FYDR pancreata by in situ imaging to show that the dramatic accumulation of recombinant pancreatic cells with age is caused by a combination of de novo recombinant events and clonal expansion . In addition, since pancreatic cells have relatively long turnover times, once a recombinant fluorescent pancreatic cell appears, it can persist within the tissue for years. Therefore, the lack of accumulation of recombinant cells in skin may result from an absence of clonal expansion, an inability to undergo de novo HR events or a short persistence of recombinant cells. Here we find that primary fibroblasts from juvenile and aged mice showed no difference in their ability to undergo HR in response to spontaneous and exogenous DNA damage. While culturing cells in vitro may not directly reflect in vivo conditions, these results nevertheless suggest that an inability to undergo de novo HR events with age does not explain the lack of accumulation of recombinant skin cells. Therefore, these observations suggest that recombinant cells do not accumulate in the skin with age because they are either short lived or do not clonally expand.
Age is a risk factor for many diseases, including cancer . Similar to aging, the accumulation of multiple mutations within cells is believed to cause cancer . Furthermore, the clonal expansion of mutant cells has been shown to be a key step in tumor formation. In fact, analysis of tumors shows that key mutations in tumor suppressors and oncogenes are often shared by most, if not all, malignant cells within the tumor [62–64]. Because most mouse models for measuring mutations generally require tissue disaggregation, information regarding clonal expansion cannot be gathered. For example, if the same mutation is observed in multiple cells, it cannot be determined if the mutation results from multiple independent events (e.g., at a mutation hot spot) or clonal expansion. Thus, many of the studies analyzing the accumulation of mutant cells with age either do not differentiate between the contribution of independent mutation events and clonal expansion [46,47,49,65] or completely remove the contribution of clonal expansion by specifically analyzing only independent mutation events [43,44]. Our previous studies , combined with the results presented here, indicate that clonal expansion contributes significantly to the overall increase in recombinant pancreatic cells with age. For example, we observe that in the pancreas >90% of the recombinant cells that accumulate in aged mice are due to clonal expansion (Wiktor-Brown et al., in preparation). Thus, analyzing clonal expansion is important for ascertaining the underlying mechanisms that contribute to the increase in mutant cell frequency with age.
The effect of aging on a number of DNA repair pathways has been examined in multiple studies. The efficiency and fidelity of some DNA repair pathways such as base excision repair and NHEJ have been shown to decrease with age [4–7,66,67]. Here, we measured recombination using two independent methods: we assessed the rate of recombination at the FYDR locus (which is designed to measure not only exchanges between sister chromatids, but also gene conversions in the absence of crossovers), and we also measured the frequency of SCEs. Together, these data show that HR in primary fibroblasts does not change with age, at least for mice up to 62 weeks of age. To note, the maximal lifespan of C57BL/6J mice is 110 ± 21 weeks ; thus, a change in HR may be seen in mice that are much older. Other studies have determined the effect of aging on HR by measuring SCEs in young and aged fibroblasts and lymphocytes. Interestingly, analyses of SCEs with age show conflicting results, with some studies showing no change in the spontaneous frequency of SCEs with age [69–71] and others indicating an increase in SCE frequency with age [72–74]. Thus, unlike some DNA repair pathways that exhibit decreased repair capacity with age, the ability of cells to undergo HR does not decrease with age, and, in fact, some studies suggest that the rate of HR may even be increased in aged cells .
HR is a critical DNA repair pathway known to contribute to aging. Here we have demonstrated that the accumulation of recombinant cells with age is tissue-specific, with pancreatic tissue showing a dramatic increase in recombinant cells and skin showing no increase. The differences in recombinant cell accumulation with age are most likely due to differences in the clonal expansion of recombinant cells within the tissues, indicating that analysis of clonal expansion is critical for understanding overall mutation burden within a tissue. Because of the ability to detect recombinant cells in vivo using fluorescence, the FYDR mice provide a unique tool to study the contribution of clonal expansion to recombinant cell frequency. Thus, in addition to age, the effects of other cancer risk factors, such as genetics and environment, on the clonal expansion of recombinant cells can be examined simply by crossing FYDR mice with transgenic mice predisposed to various cancers or by treating mice with different environmental agents. Determining the relative importance of clonal expansion to mutant cell frequency within different tissues is fundamental to our understanding of mechanisms that modulate susceptibility of various tissues to age associated degeneration and cancer.
We are grateful to Saja FakhralDeen and Jenn Sauchuk for technical assistance. We thank Glenn Paradis of the MIT Center for Cancer Research Flow Cytometry Facility and the MIT Division of Comparative Medicine and the MIT Center for Environmental Health Sciences(NIH ES02109) for their support. This work was supported primarily by CA84740 with partial support from 5-P01-CA26731-26, DE-FG01-04ER04-21. D.M.W.-B. was supported by the NIH/NIGMS Interdepartmental Biotechnology Training Program GM008334, and C.A.H was supported by T32-ES07020.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.